Home Missions Cystic Fibrosis Leber’s Congenital Amaurosis About us Careers Investor Relations Contact Changing lives Changing lives is what drives us at ProQR Therapeutics. With a highly energetic team of professionals we strive to make a meaningful impact on the lives of patients and the people around them. By combining innovative technologies and entrepreneurism, ProQR is developing products to potentially transform the lives of patients suffering from severe genetic disorders. Ongoing clinical trials QR-010 for cystic fibrosis Details Join Us Applying top-notch science to develop drugs for patients in need is what drives us. With an ingenious and persistent team of pioneers we love to welcome people who can accelerate our mission. Do you think you are ready to become a ProQRian? Let us know! Read more Severe Genetic Disorders More than 70,000 patients worldwide suffer from cystic fibrosis, a genetic disease with a limited life expectancy. Leber’s congenital amaurosis affects approximately 15,000 patients in the Western world and there is currently no disease modifying treatment available for this blinding disease. Learn more about our missions and how we aim to change the course of severe genetic disorders. Read more Meet us October 8-10th 2015, Phoenix, AZ - North American Cystic Fibrosis Conference (NACFC) © 2014 ProQR Therapeutics. All Rights Reserved. ProQR is a registered trademark. Disclaimer

Home Missions Cystic Fibrosis Leber’s Congenital Amaurosis About us Careers Investor Relations Contact Disclaimer This website contains forward-looking statements about potential therapeutic uses and effects of ProQR Therapeutics’ products, including but not limited to our technologies. Actual results may differ materially depending on the actual therapeutic effect of the products, whether trials are initiated, the actual timing and results of the (pre)clinical trials, the actual timing and content of regulatory submissions and decisions of the FDA, EMEA and other regulatory bodies. We expect that our sources of income, if any, for the next several years will continue to primarily consist of payments under collaborative agreements. In addition, we may not successfully develop, commercialize, manufacture or market any products or generate sufficient revenues to ever achieve or sustain profitability. ProQR Therapeutics seeks to ensure that the information on this website (other than information accessed by hypertext links) is accurate. However no representation or warranty is made and no liability is accepted as to the accuracy, completeness or any other aspect of the information or links contained on the website. This website does not give any advice or make any recommendation (and should not be construed as so doing) and should not be relied upon. Any and all liability which might arise from your use or reliance on the information or links contained on the website is excluded. ProQR Therapeutics N.V. Darwinweg 24, 2333 CR Leiden, The Netherlands +31 88 166 7000 info@proqr.com © 2014 ProQR Therapeutics. All Rights Reserved. ProQR is a registered trademark. Disclaimer